- Home
- CCIF vs PRLD Comparison
CCIF vs PRLD Comparison
Compare CCIF & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CCIF | PRLD |
|---|---|---|
| Founded | 2011 | 2016 |
| Country | United States | |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 84.8M | 69.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CCIF | PRLD |
|---|---|---|
| Price | $3.30 | $2.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 76.9K | ★ 286.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 25.90% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.43 | $0.61 |
| 52 Week High | $10.16 | $4.22 |
Technical Indicators
Market Signals| Indicator | CCIF | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | 18.33 | 50.15 |
| Support Level | $3.97 | $1.95 |
| Resistance Level | $4.10 | $2.37 |
| Average True Range (ATR) | 0.19 | 0.21 |
| MACD | -0.06 | 0.01 |
| Stochastic Oscillator | 11.99 | 59.65 |
Price Performance
Historical ComparisonAbout CCIF Carlyle Credit Income Fund Shares of Beneficial Interest
Carlyle Credit Income Fund is a non-diversified, closed-end management investment company. The Fund's primary investment objective is to generate current income, with a secondary objective to generate capital appreciation. The Fund seeks to achieve its investment objective by investing predominantly in equity and junior debt tranches of collateralized loan obligations, that are collateralized by a portfolio consisting mainly of below-investment-grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.